Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 9/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.40 |
| ▸ | CCR2 | P41597 | 8/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5623662 | 0.93 | TACR1 (0.41) | TACR1GPBAR1CCR2NPY1RNPY5R | |
| SCHEMBL5623686 | 0.90 | TACR1 (0.40) | TACR1GPBAR1CCR2 | |
| SCHEMBL5627070 | 0.90 | TACR1 (0.40) | TACR1GPBAR1CCR2NPY1RNPY5R | |
| SCHEMBL4508861 | 0.78 | CETP (0.32) | TACR1 | |
| SCHEMBL4496944 | 0.78 | GPBAR1 (0.35) | TACR1GPBAR1CCR2 | |
| SCHEMBL5046166 | 0.76 | DRD4 (0.40) | TACR1GPBAR1CCR2 | |
| SCHEMBL5626484 | 0.76 | TACR1 (0.40) | TACR1GPBAR1CCR2 | |
| SCHEMBL5802941 | 0.73 | TACR1 (0.52) | TACR1GPBAR1 | |
| SCHEMBL5623657 | 0.72 | TACR1 (0.41) | TACR1GPBAR1CCR2 | |
| SCHEMBL5626481 | 0.72 | TACR1 (0.41) | TACR1GPBAR1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | TACR1 3300/4885GPBAR1 270/4885CCR2 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.